These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 34158025)

  • 1. Systems glycobiology for discovering drug targets, biomarkers, and rational designs for glyco-immunotherapy.
    Chiang AWT; Baghdassarian HM; Kellman BP; Bao B; Sorrentino JT; Liang C; Kuo CC; Masson HO; Lewis NE
    J Biomed Sci; 2021 Jun; 28(1):50. PubMed ID: 34158025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent updates in cancer immunotherapy: a comprehensive review and perspective of the 2018 China Cancer Immunotherapy Workshop in Beijing.
    Li Z; Song W; Rubinstein M; Liu D
    J Hematol Oncol; 2018 Dec; 11(1):142. PubMed ID: 30577797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of miRNAs in immune responses and immunotherapy in cancer.
    Cortez MA; Anfossi S; Ramapriyan R; Menon H; Atalar SC; Aliru M; Welsh J; Calin GA
    Genes Chromosomes Cancer; 2019 Apr; 58(4):244-253. PubMed ID: 30578699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structures of Immune Checkpoints: An Overview on the CD28-B7 Family.
    Liu W; Zang X
    Adv Exp Med Biol; 2019; 1172():63-78. PubMed ID: 31628651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translation of cancer immunotherapy from the bench to the bedside.
    Guo Q; Huang F; Goncalves C; Del Rincón SV; Miller WH
    Adv Cancer Res; 2019; 143():1-62. PubMed ID: 31202357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of immune checkpoint therapy for cancer.
    Fritz JM; Lenardo MJ
    J Exp Med; 2019 Jun; 216(6):1244-1254. PubMed ID: 31068379
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint inhibitors win the 2018 Nobel Prize.
    Huang PW; Chang JW
    Biomed J; 2019 Oct; 42(5):299-306. PubMed ID: 31783990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T Cell Therapy Progress and Challenges for Solid Tumors.
    Stern LA; Jonsson VD; Priceman SJ
    Cancer Treat Res; 2020; 180():297-326. PubMed ID: 32215875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nobel committee honors tumor immunologists.
    Rotte A; D'Orazi G; Bhandaru M
    J Exp Clin Cancer Res; 2018 Oct; 37(1):262. PubMed ID: 30376854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Putting the Immunologic Brakes on Cancer.
    Wolchok J
    Cell; 2018 Nov; 175(6):1452-1454. PubMed ID: 30500529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding and overcoming the resistance of cancer to PD-1/PD-L1 blockade.
    Shergold AL; Millar R; Nibbs RJB
    Pharmacol Res; 2019 Jul; 145():104258. PubMed ID: 31063806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immuno-pharmacodynamics for evaluating mechanism of action and developing immunotherapy combinations.
    Parchment RE; Voth AR; Doroshow JH; Berzofsky JA
    Semin Oncol; 2016 Aug; 43(4):501-13. PubMed ID: 27663482
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Personalized Immuno-Oncology.
    Jain KK
    Med Princ Pract; 2021; 30(1):1-16. PubMed ID: 32841942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting glyco-immune checkpoints for cancer therapy.
    Manni M; Läubli H
    Expert Opin Biol Ther; 2021 Aug; 21(8):1063-1071. PubMed ID: 33502268
    [No Abstract]   [Full Text] [Related]  

  • 15. [Cancer immunotherapy crowned with Nobel Prize in Physiology or Medicine awarded to James Allison and Tasuku Honjo].
    Teillaud JL
    Med Sci (Paris); 2019 Apr; 35(4):365-366. PubMed ID: 31038115
    [No Abstract]   [Full Text] [Related]  

  • 16. Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules.
    D'Arrigo P; Tufano M; Rea A; Vigorito V; Novizio N; Russo S; Romano MF; Romano S
    Curr Med Chem; 2020; 27(15):2402-2448. PubMed ID: 30398102
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Nobel Prize-worthy pursuit: cancer immunology and harnessing immunity to tumour neoantigens.
    Altmann DM
    Immunology; 2018 Nov; 155(3):283-284. PubMed ID: 30320408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of PD-L1 N-linked glycosylation on cancer therapy and clinical diagnosis.
    Wang YN; Lee HH; Hsu JL; Yu D; Hung MC
    J Biomed Sci; 2020 Jul; 27(1):77. PubMed ID: 32620165
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tumour glyco-code as a novel immune checkpoint for immunotherapy.
    RodrÍguez E; Schetters STT; van Kooyk Y
    Nat Rev Immunol; 2018 Mar; 18(3):204-211. PubMed ID: 29398707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [IMMUNOTHERAPY WITH CHECKPOINT INHIBITORS (ICPI) AND IMMUNE RELATED ADVERSE EVENTS (IRAE'S)].
    Ben Zvi C; Ehrenfeld M; Shoenfeld Y
    Harefuah; 2020 Jul; 159(7):508-515. PubMed ID: 32720769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.